Otsuka Group News

Keyword search

Search by company	Otsuka Holdings Otsuka Pharmaceutical Otsuka Pharmaceutical Factory Taiho Pharmaceutical Otsuka Warehouse Otsuka Chemical Otsuka Foods Otsuka Medical Devices Other
Search by category^*	Pharmaceuticals Business Nutraceuticals Business Consumer Products Business Others Products R&D Personnel Corporate * Business categories are based on the business segments described in the financial announcements.
Search by release date	-

September 16, 2014
Otsuka Pharmaceutical

Otsuka Pharmaceutical Launches "Next Generation Athlete Development Project" at the 17th Asian Games Junior athletes experience world-class atmosphere at Asia's largest competition
September 16, 2014
Otsuka Pharmaceutical

A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Approval in Japan for Otsuka's Major BCR-ABL mRNA Measurement Kit
September 12, 2014
Otsuka Chemical

Otsuka Chemical to Acquire Higashiyama Film, Entering into Functional Film Market
September 11, 2014
Otsuka Pharmaceutical

New Calorie Mate Block "Plain" First simple, unadorned flavor marks a return to Calorie Mate origins after 32 years
September 9, 2014
Otsuka Pharmaceutical

New SoyCarat Chili Pepper Flavor Spicy version of healthy, low GI soy snack packs grown-up appeal
September 8, 2014
Otsuka Pharmaceutical

New Antituberculosis Drug Deltyba® in 50 mg Tablets, Available to Patients in Japan Starting September 26
September 5, 2014
Otsuka Pharmaceutical Factory

Otsuka Pharmaceutical Factory announces PROCESS LEAD, a chew and swallow managing food, launched on September 5, 2014
August 28, 2014
Otsuka Pharmaceutical

Acquisition of Jasmine, Leading Brazilian Health Food Company
August 26, 2014
Otsuka Holdings

Otsuka announces the Second Medium-Term Management Plan
August 6, 2014
Otsuka Pharmaceutical

UL･OS Announces New Skin Conditioner Promoting the Habit of Skin Care for Middle-Aged Men
August 5, 2014
Otsuka Pharmaceutical

Otsuka Welfare Clinic for Refugees in Pakistan Awarded Foreign Minister's Commendation
August 4, 2014
Otsuka Pharmaceutical

E Keppra® 500 mg Injectable For Monotherapy Treatment of Epilepsy Submitted For Regulatory Review in Japan
July 31, 2014
Taiho Pharmaceutical

Taiho Pharmaceutical Announces Termination of Phase III Clinical Trial of the Angiogenesis Inhibitor TSU-68 (orantinib) in Patients with Hepatocellular Carcinoma
July 25, 2014
Otsuka Holdings

Otsuka announces 2014 second quarter U.S. net sales figures of ABILIFY®
July 25, 2014
Taiho Pharmaceutical

Phase III Clinical Study of S-1 in Patients with Advanced Hepatocellular Carcinoma Did Not Meet Its Primary Endpoint
July 23, 2014
Taiho Pharmaceutical

Taiho Pharmaceutical Invests US$ 30 Million in Remiges BioPharma Fund, LP to Foster Early Biotech Start-ups
July 14, 2014
Otsuka Holdings

OTSUKA AND LUNDBECK SUBMIT NEW DRUG APPLICATION IN THE US FOR BREXPIPRAZOLE FOR THE TREATMENT OF SCHIZOPHRENIA AND AS ADJUNCTIVE THERAPY FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
July 14, 2014
Otsuka Pharmaceutical

Otsuka and Lundbeck Submit New Drug Application in The US for Brexpiprazole for The Treatment of Schizophrenia and as Adjunctive Therapy for The Treatment of Major Depressive Disorder
July 9, 2014
Otsuka Pharmaceutical Factory

J.O. Pharma Co., Ltd. to expand its production facility in Izumo City
July 4, 2014
Otsuka Pharmaceutical

After 40 Years, A New Drug For The Treatment Of Tuberculosis In Japan Deltyba® (delamanid) Is The First Drug Approved In Japan Specifically For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)
July 4, 2014
Otsuka Pharmaceutical

E Keppra® Injectable Receives Marketing Authorization in Japan Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged Four and Over
July 2, 2014
Taiho Pharmaceutical

Application for the Additional Indication of Febrile Neutropenia for ZOSYN®, an Injectable Antibiotic Combined with β-Lactamase Inhibitor
June 30, 2014
Taiho Pharmaceutical

Taiho Pharmaceutical Announces Results from TAS-102 Global Phase III RECOURSE Trial in Refractory Metastatic Colorectal Cancer
June 27, 2014
Otsuka Pharmaceutical

Regulatory Approval Received in Japan For L-Cartin® FF Tablets 100 mg・250 mg Doses That Incorporate Carnitine in Free Form (FF*) Enables Medical Professionals to Conveniently Switch Patients Among the Three Free-Form Formulations – Tablet, Oral Solution and Injection
June 20, 2014
Otsuka Pharmaceutical

Meptin®, a Fast-acting Bronchodilator to Treat Asthma and COPD, Will Become Available in Japan on July 2 in a New Form as Meptin® Swinghaler® 10μg 100Puffs
June 17, 2014
Otsuka Pharmaceutical Factory

Egypt Otsuka acquires an Egyptian intravenous infusion manufacturing and distribution company
June 16, 2014
Otsuka Pharmaceutical Factory

Otsuka Pharmaceutical Factory Announces Personnel Changes
June 11, 2014
Taiho Pharmaceutical

Taiho Pharmaceutical Announces Personnel Changes
June 10, 2014
Otsuka Warehouse

Otsuka Warehouse Announces Personnel Changes
June 4, 2014
Taiho Pharmaceutical

Data from Phase II Trial of ET-743 (trabectedin), a Novel Antitumor Agent, in Patients with Malignant Soft Tissue Sarcoma Presented at ASCO®